Physician profile
James R Hoffmann
NPI 1043570757
$3,662.03
in general payments reported to CMS, 2019-2025
23 companies · $814 in 2025
The $814 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2020: $236 · 2021: $308 · 2022: $459 · 2023: $887 · 2024: $803 · 2025: $814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,365 · Long Term Medical Supply Or Device Loan: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,364.78 |
| Long Term Medical Supply Or Device Loan | $140.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,089.44 | 2022-2025 | |
| Alcon Vision LLC | $668.25 | 2019-2025 | Clareon Panoptix Pro, Clareon, Hydrus Microstent |
| Biotissue Holdings INC. | $391.36 | 2021-2024 | |
| Ocular Therapeutix, INC. | $281.70 | 2022-2023 | Dextenza |
| Bausch & Lomb Americas INC. | $278.05 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Allergan, INC. | $203.45 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $146.33 | 2021-2024 | Acthar |
| Novartis Pharmaceuticals Corporation | $80.48 | 2021-2023 | |
| Thea Pharma INC. | $59.92 | 2024-2025 | Iyuzeh |
| Ivantis, INC | $54.60 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $52.15 | 2019 | |
| Omeros Corporation | $44.67 | 2020-2021 | |
| Glaukos Corporation | $44.61 | 2019-2023 | |
| Oyster Point Pharma, INC. | $43.39 | 2023 | Tyrvaya |
| Rxsight INC | $41.42 | 2024-2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $34.30 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $33.04 | 2023 | Cequa, Xelpros |
| Rayner Intraocular Lenses Limited | $32.48 | 2022-2024 | Rayone Emv, Rayone Aspheric, Omidria |
| Amgen INC. | $22.24 | 2025 | Tepezza |
| Sight Sciences, INC. | $17.84 | 2024 | Omni Surgical System |
| Carl Zeiss Meditec USA, INC. | $17.55 | 2022 | |
| Eyepoint US, INC. | $13.58 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hoffmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.